TUR 004

Drug Profile

TUR 004

Alternative Names: TUR-004

Latest Information Update: 21 Nov 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Turing Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2015 Phase-I clinical trials in Epilepsy (epileptic encephalopathies) (In volunteers) in USA (PO)
  • 26 Oct 2015 TUR 004 receives Fast Track designation for Epilepsy [epileptic encephalopathies, PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top